Abstracts
Objectives
To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to giant cell arteritis (GCA) in a cohort of Italian patients.
Methods
176 consecutive Italian patients with biopsy-proven GCA and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism.
Results
No statistically significant difference in the Δ32CCR5 allele frequency between GCA patients (5.1 %) and controls (2.8 %) was observed (p = 0.109). Carriers of the CCR5Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were similarly represented in the two groups.
Conclusions
Our results do not support a role for the CCR5Δ32 polymorphism in determining susceptibility to GCA.
Similar content being viewed by others
References
Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymialgia rheumatica. Arthritis Rheum. 2009;61:1454–61.
Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WR. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003;33:38–48.
Weyand CM, Hicok KC, Hunder GG, Goronzy J. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest. 1992;90:2355–61.
Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Macchioni P, et al. Interleukin-10 promoter polymorphisms in giant cell arteritis. Arthritis Rheum. 2006;54:4011–7.
Salvarani C, Casali B, Nicoli D, Farnetti E, Macchioni P, Catanoso MG, et al. Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum. 2003;48:3219–23.
Ward SG, Marelli-Berg FM. Mechanisms of chemokine and antigen-dependent T-lymphocyte navigation. Biochem J. 2009;418:13–27.
Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–21.
Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol. 2004;36:35–8.
Brühl H, Vielhauer V, Weiss M, Mack M, Schlöndorff D, Segerer S. Expression of DARC, CXCR3 and CCR5 in giant cell arteritis. Rheumatology. 2005;44:309–13.
O’Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev. 2000;177:99–111.
Martens HA, Kallenberg CG, Bijl M. Role of CCR5 delta32 bp deletion in RA and SLE. Autoimmunity. 2009;42:260–2.
Petrek M, Gibejova A, Drabek J, Mrazek F, Kolek V, Weigl E, et al. CC chemokine receptor 5 (CCR5) mRNA expression in pulmonary sarcoidosis. Immunol Lett. 2002;80(189):93.
Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology. 2003;61(238):40.
Carmona FD, Rodríguez-Rodríguez L, Castañeda S, Miranda-Filloy JA, Morado IC, Narváez J, et al. Role of the CCR5/Δ32CCR5 polymorphism in biopsy-proven giant cell arteritis. Hum Immunol. 2011;72:458–61.
Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum. 2001;30:249–56.
Restuccia G, Cavazza A, Boiardi L, Pipitone N, Macchioni P, Bajocchi G, et al. Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis. Arthritis Rheum. 2012;64:549–56.
Yang B, Houlberg K, Millward A, Demaine A. Polymorphisms of chemokine and chemokine receptors in type 1 diabetes mellitus and its complications. Cytokine. 2004;26:114–21.
Odum N, Bregenholt S, Eriksen KW, Skov S, Ryder LP, Bendtzen K, et al. The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for the development of human Th1 cells. Tissue Antigens. 1999;54:572–7.
Berce V, Repnik K, Potocnik U. Association of CCR5-delta32 mutation with reduced risk of nonatopic asthma in Slovenian children. J Asthma. 2008;45:780–4.
Petrek M, Cermáková Z, Hutyrová B, Miceková D, Drábek J, Rovensky J, et al. CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2002;20:701–3.
Pokorny V, McQueen F, Yeoman S, Merriman M, Merriman A, Harrison A, et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis. 2005;64:487–90.
Zhou Y, Huang D, Farver C, Hoffman GS. Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener’s granulomatosis. J Rheumatol. 2003;30:1541–7.
Petrek M, Drábek J, Kolek V, Zlámal J, Welsh KI, Bunce M, et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2000;162:1000–3.
Atzeni F, Boiardi L, Casali B, Farnetti E, Sarzi-Puttini PC, Pipitone N et al. CC Chemokine receptor 5 polymorphism in italian patients with Behçet’s disease. Rhematology 2012 (in press).
Boiardi L, Vaglio A, Nicoli D, Farnetti E, Palmisano A, Pipitone N, et al. CC chemokine receptor 5 polymorphism in chronic periaortitis. Rheumatology. 2011;50:1025–32.
Ghilardi G, Biondi ML, Battaglioli L, Zambon A, Guagnellini E, Scorza R. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. J Vasc Surg. 2004;40:995–1000.
Salvarani C, Boiardi L, Timms JM, Silvestri T, Ranzi A, Macchioni PL, et al. Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. Clin Exp Rheumatol. 2000;18:591–5.
Zhou Y, Kurihara T, Ryseck RP, Yang Y, Ryan C, Loy J, et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol. 1998;160:4018–25.
Ajuebor MN, Wondimu Z, Hogaboam CM, Le T, Proudfoot AE, Swain MG. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am J Pathol. 2007;170:1975–88.
Takeuchi A, Usui Y, Takeuchi M, Hattori T, Kezuka T, et al. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response. Invest Ophthalmol Vis Sci. 2005;46:3753–60.
Ramshaw AL, Parums DV. Immunohistochemical characterization of inflammatory cells associated with advanced atherosclerosis. Histopathology. 1990;17:543–52.
Ramshaw AL, Roskell DE, Parums DV. Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol. 1994;47:721–7.
Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484–91.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Pazzola, G., Boiardi, L., Casali, B. et al. CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. Mod Rheumatol 23, 851–855 (2013). https://doi.org/10.1007/s10165-012-0751-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-012-0751-5